These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
980 related articles for article (PubMed ID: 27528027)
1. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027 [TBL] [Abstract][Full Text] [Related]
2. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889 [TBL] [Abstract][Full Text] [Related]
3. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270 [TBL] [Abstract][Full Text] [Related]
4. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412 [TBL] [Abstract][Full Text] [Related]
5. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer. Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944 [TBL] [Abstract][Full Text] [Related]
6. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995 [TBL] [Abstract][Full Text] [Related]
7. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930 [TBL] [Abstract][Full Text] [Related]
8. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine. Miller AL; Fehling SC; Vance RB; Chen D; Brown EJ; Hossain MI; Heard EO; Andrabi SA; Wang H; Yang ES; Buchsbaum DJ; van Waardenburg RCAM; Bellis SL; Yoon KJ Cancer Lett; 2024 Jun; 592():216919. PubMed ID: 38704133 [TBL] [Abstract][Full Text] [Related]
12. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Zhang X; Zegar T; Weiser T; Hamdan FH; Berger BT; Lucas R; Balourdas DI; Ladigan S; Cheung PF; Liffers ST; Trajkovic-Arsic M; Scheffler B; Joerger AC; Hahn SA; Johnsen SA; Knapp S; Siveke JT Int J Cancer; 2020 Nov; 147(10):2847-2861. PubMed ID: 32599645 [TBL] [Abstract][Full Text] [Related]
13. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. Wang B; Fan P; Zhao J; Wu H; Jin X; Wu H J Exp Clin Cancer Res; 2018 Sep; 37(1):224. PubMed ID: 30201002 [TBL] [Abstract][Full Text] [Related]
14. SAA1 is upregulated in gastric cancer-associated fibroblasts possibly by its enhancer activation. Yasukawa Y; Hattori N; Iida N; Takeshima H; Maeda M; Kiyono T; Sekine S; Seto Y; Ushijima T Carcinogenesis; 2021 Feb; 42(2):180-189. PubMed ID: 33284950 [TBL] [Abstract][Full Text] [Related]
15. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272 [TBL] [Abstract][Full Text] [Related]
16. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473 [TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. Nguyen AH; Elliott IA; Wu N; Matsumura C; Vogelauer M; Attar N; Dann A; Ghukasyan R; Toste PA; Patel SG; Williams JL; Li L; Dawson DW; Radu C; Kurdistani SK; Donahue TR Oncotarget; 2017 Mar; 8(12):19074-19088. PubMed ID: 27894105 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638 [TBL] [Abstract][Full Text] [Related]
19. Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma. Lee S; Rellinger EJ; Kim KW; Craig BT; Romain CV; Qiao J; Chung DH Surgery; 2015 Sep; 158(3):819-26. PubMed ID: 26067464 [TBL] [Abstract][Full Text] [Related]
20. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. Kumar K; DeCant BT; Grippo PJ; Hwang RF; Bentrem DJ; Ebine K; Munshi HG JCI Insight; 2017 Feb; 2(3):e88032. PubMed ID: 28194432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]